General Electric (GE) is a multinational conglomerate with well-diversified chains of businesses, but nowadays it has become more of a controversial company with many investors questioning the strategies being adopted by its CEO, Jeffrey Immelt. There are many people including renowned analysts that now hold divergent views about the potential of the company for upside growth. Really, the unit prices of GE stock have consistently lagged behind their peers in the industrial sector in the last one decade. That alone is enough for the investing public to deride the current business strategies of the company. GE�� dividend policy under Immelt is another source of concern for many investors.
Indeed, the majority of shareholders who bought the shares of General Electric a short while ago may not be comfortable with the inability of the stock to break above the $25 price level except those who bought into the company at $6 a share some years ago. However, I supposed that those who are net buyers of GE stocks should wish for low prices for an extended period so that they could accumulate more shares of the company.
Best Solar Companies To Own In Right Now: Nomura Holdings Inc ADR (NMR)
Nomura Holdings, Inc. provides financial services in Japan and internationally. The company operates in three divisions: Retail, Asset Management, and Wholesale. The Retail division primarily offers investment consultation services to retail clients. It also provides various financial instruments, such as stocks, debt securities, investment trusts, and variable annuity insurance products for the short, medium, and long term. As of March 31, 2011, this division operated a network of approximately 174 branches. The Asset Management division involves in the development and management of investment trusts. This division also offers investment advisory services to public and private pensions, governments and their agencies, central banks, and institutional investors. The Wholesale division engages in the fixed income and equity trading, and asset finance businesses. It provides debt securities, foreign currencies, and stocks, as well as related derivatives; and equities securit ies and equity-linked derivatives; and execution services, such as algorithmic trading and transaction cost analysis. This division also involves in underwriting various types of stocks, convertible and exchangeable securities, investment grade debt, sovereign and emerging market debt, high yield debt, structured securities, and other securities; offers financial advisory services and solutions on business transactions, including mergers and acquisitions, divestitures, spin-offs, capital structuring, corporate defense activities, leveraged buyouts, and risk solutions; and operates private equity investment business. The company primarily serves individuals, corporations, financial institutions, governments, and governmental agencies, as well as retail and asset management clients. Nomura Holdings, Inc. was founded in 1925 and is headquartered in Tokyo, Japan.
Advisors' Opinion:- [By WWW.MARKETWATCH.COM]
LOS ANGELES (MarketWatch) -- Japanese stocks have ended with losses in every session this week, and sure enough, the Nikkei Average (JP:NIK) was down 0.6% in early Friday trade, though off an opening 0.8% defecit, while the Topix carried a 0.7% loss. Overnight losses for the U.S. and further strength in the yen (with the dollar falling to 楼101.28 from 楼101.56 a day earlier) helped drag the market lower, as did results from Fast Retailing Co. (JP:9983) (FRCOF) , the shares of which hold the heaviest weighting on Nikkei Average. Fast Retailing said that while its Uniqlo brand was doing great business, weakness for its J Brand luxury demin label helped send September-May profit down 4% and prompted another cut to Fast's full-year outlook. Consequently, its shares traded 0.7% lower, though rivals Takashimaya Co. (JP:8233) and J. Front Retailing Co. (JP:3086) (JFROF) also saw losses of 0.6% and 0.5%, respectively. Among other decliners, Sony Corp. (JP:6758) (SNE) lost 0.7%, Toshiba Corp. (JP:6502) (TOSYY) fell 2.1%, Kawasaki Heavy Industries Ltd. (JP:7012) (KWHIY) fell 1.5%, Toyota Motor Corp. (JP:7203) (TM) and Nissan Motor Co. (JP:7201)
- [By Dan Carroll]
Japan's Nikkei (NIKKEIINDICES: ^NI225 ) has topped indexes around the world this year, but investors wouldn't know it by looking at its recent performance. One need look no further than the yen's fluctuations as the country's central bank tries to weaken its currency through stimulus. Financial stocks are the kings of volatility across the Pacific: Nomura Holdings (NYSE: NMR ) has posted a whopping 129% gain over the past year, but over the last month the stock has performed horribly, losing more than 9%.
- [By Dan Carroll]
The best certainly hasn't come this week in the financial sector, however. Financial stocks have surged in Japan on stimulus optimism, but fears over its future have blasted this sector's best over the last five days. Nomura Holdings (NYSE: NMR ) , one of the biggest victims of investor fear, fell 11.5% over the course of the week. Nomura has done well lately on the back of easy money and is preparing to increase sales staff in Europe, Asia, and the Americas to boost profitability overseas. While investors have panicked over Thursday's drop and bailed out of Nomura's stock, this is one financial firm looking strong. Like the Nikkei, Nomura has been a victim of its own success this year: With the stock's 42% year-to-date rise, a correction was bound to occur.
Best Low Price Companies To Buy For 2014: Sagent Pharmaceuticals Inc.(SGNT)
Sagent Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, sources, and markets pharmaceutical products, principally injectable-based generic equivalents to branded products in the United States. It offers a range of products across anti-infective, oncolytic, and critical care indications in various presentations, including single-and multi-dose vials, pre-filled ready-to-use syringes, and premix bags. The company?s anti-infective products include Levofloxacin, a fluoroquinolone antibacterial for the treatment of various infections caused by susceptible bacteria in adults of age 18 years or older; and Cefepime, an antibiotic used to treat infections of the urinary tract, and skin and skin structure, as well as moderate to severe pneumonia, intra-abdominal infections, and as empiric therapy for febrile neutropenic patients. Its oncology products comprise Gemcitabine, a nucleoside metabolic inhibitor used for the treatment of ovarian, breast, lung, and panc reatic cancers; and Topotecan, a topoisomerase inhibitor for small cell lung cancer sensitive disease. The company also offers critical care products consisting of Adenosine, an antiarrhythmic used for the treatment of cardiac rhythm disturbances; and Heparin, an anticoagulant used to prevent and treat blood clotting during and after surgery and dialysis. As of December 31, 2011, it marketed 33 generic injectable products; and had a new product pipeline that included 36 products represented by 63 Abbreviated New Drug Applications (ANDAs). The company sells its products to pharmaceutical wholesale companies, which then distribute the products to end-user hospitals, long-term care facilities, alternate care sites, and clinics. The company was formerly known as Sagent Holding Co. and changed its name to Sagent Pharmaceuticals, Inc. in April 2011. Sagent Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Schaumburg, Illinois.
Advisors' Opinion:- [By James Brumley]
In no particular order…
Sagent Pharmaceuticals (SGNT)Though Sagent Pharmaceuticals (SGNT) makes a few dozen generic drugs and has a similar number in the works, odds are good most investors couldn’t name a single one of them… and that’s a good thing for anyone on the hunt for cheap stocks from the pharma world.
Best Low Price Companies To Buy For 2014: Universal Health Services Inc. (UHS)
Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, behavioral health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The company�s hospitals offer various services comprising general and specialty surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic care, coronary care, pediatric services, pharmacy services, and/or behavioral health services. As of February 24, 2012, it owned and/or operated 25 acute care hospitals and 198 behavioral health centers located in 36 states, Puerto Rico, and the U.S. Virgin Islands, as well as Washington, D.C. The company also operates six surgical hospitals, and surgery and radiation oncology centers located in four states and Puerto Rico. Universal Health Services, Inc. was founded in 1978 and is headquartered in King of Prussia, Pennsylvania.
Advisors' Opinion:- [By Ben Levisohn]
Tenets plunge has helped drag other healthcare stocks lower.�Community Health (CYH) has dropped 3.6% to $42.21,�HCA Holdings (HCA) has fallen 2.1% to $46.72 and�Universal Health Services�(UHS) is off 1% at $80.59.
- [By Rich Duprey]
Hospital chain operator�Universal Health Services� (NYSE: UHS ) announced today its third-quarter dividend of $0.05 per share, the same rate it's paid since 2010.
- [By John Moore]
Universal Health Services (NYSE: UHS ) has aggressively attacked a grown concern in America: diabetes. The company is currently developing specialty services to treat type 1 diabetes and mental health.�Universal Health Services provides expert home, hospice and personal assistance care. They specialize in providing nurses who are skilled in diabetes and disease management.�
Best Low Price Companies To Buy For 2014: Rosetta Genomics Ltd (ROSG)
Rosetta Genomics Ltd., incorporated on March 9, 2000, is seeking to develop and commercialize diagnostic tests based on discovered group of genes known as microRNAs. The Company has established a clinical laboratory improvement amendment (CLIA)-certified laboratory in Philadelphia, which enables it to develop, validate and commercialize its own diagnostic tests applying its microRNA technology. In July 2011, the Company launched its fifth product - miRview lung. As of December 31, 2011, the Company launched five tests based on its five microRNA technologies: miRview mets; miRview mets2; miRview squamous; miRview meso, and miRview lung.
Rimonim Consortium
In January 2011, the Company joined the Rimonim Consortium, which is supported by the Office of the Chief Scientist at the Ministry of Industry, Trade and Labor of the State of Israel, or the OCS. The purpose of the consortium is to develop RNA interference, or RNAi, -based therapeutics.
Rosetta Green
Rosetta Green Ltd. is an Israeli subsidiary of the Company, which was established to leverage its capabilities into the areas of cleantech and plant biotech by using its microRNA technologies to develop plants and algae more suitable for various applications, such as feedstocks for biofuels and agriculture. Research at the Rosetta Green project has been shown to develop algal strains with oil content, to discover potential novel microRNAs from commercially-important algae and to identify drought-regulated microRNAs in plants.
The Company competes with Pathwork Diagnostics, Inc., Biotheranostics, Inc., Combimatrix Corporation, Alnylam Pharmaceuticals, Inc., Asuragen Inc., Exiqon A/S, Life Technologies Corporation, Isis Pharmaceuticals, Merck & Co., Inc., Santaris Pharma A/S, and Regulus Therapeutics.
Advisors' Opinion:- [By John Udovich]
On Tuesday, small cap cancer diagnostic stock Myriad Genetics, Inc (NASDAQ: MYGN) jumped 11.42% in one day, meaning its worth taking a closer look at the stock along with the performance of small cap cancer diagnostic stocks like Rosetta Genomics Ltd (NASDAQ: ROSG) and�Genomic Health, Inc (NASDAQ: GHDX) plus mid cap diagnostic stock Quest Diagnostics Inc (NYSE: DGX). I should mention that we have had�Myriad Genetics in our SmallCap Network Elite Opportunity (SCN EO) portfolio since February 5th and we are already up 18.50%���a nice return in just two weeks time.
- [By John Udovich]
The National Cancer Institute estimates that about ten million Americans have or have had some form of cancer with the overall costs of the disease topping $126 billion annually ��meaning there is a big market for small cap cancer diagnostic stocks like Rosetta Genomics Ltd. (NASDAQ: ROSG), Genetic Technologies Limited (NASDAQ: GENE) and MetaStat Inc (OTCBB: MTST) just in the US alone without considering global cancer figures. After all, catching and doing something about cancer early on is critical to increase survival rates and bring down the cost of treatment. With that in mind, here are three small cap cancer diagnostic stocks helping to lead the fight to diagnose and stop cancer:
- [By Anthony Mirhaydari]
For now, I continue to recommend investors maintain a cautious stance, focusing on the buying interest coming into safe-haven assets like U.S. Treasury bond and precious metals while booking profits in biotech stocks that have been red hot this month. The leveraged Direxion 3x Treasury Bond Bull (TMF) is up nearly 7% in my Edge Letter Sample Portfolio since it was added on Jan. 10. I just sold Tower Hill Mines (THM) and Rosetta Genomics (ROSG) for gains of 46% and 18% respectively.
- [By John Udovich]
Small cap cancer diagnostic stock�Myriad Genetics, Inc (NASDAQ: MYGN) jumped to a five year high on Wednesday�thanks to good�news that the�government will be paying a heftier reimbursement for its main test than previously feared, meaning its worth taking a closer look at the stock along with small cap cancer diagnostic stocks like Rosetta Genomics Ltd (NASDAQ: ROSG) and�Genomic Health, Inc (NASDAQ: GHDX) plus mid cap diagnostic stock Quest Diagnostics Inc (NYSE: DGX). I should also mention that Myriad Genetics has been in our SmallCap Network Elite Opportunity (SCN EO) portfolio since early February and we are now up some 32.5% since then ��thanks in part to the shorts being put in a short squeeze.
Best Low Price Companies To Buy For 2014: Merit Medical Systems Inc.(MMSI)
Merit Medical Systems, Inc. designs, develops, manufactures, and markets medical devices for use in interventional and diagnostic procedures worldwide. It offers cardiology and radiology devices, which assist in diagnosing and treating coronary arterial disease, peripheral vascular disease, and other non-vascular diseases. The company?s cardiology and radiology devices include inflation devices; hemostasis valves; vascular retrieval devices; vascular access products; diagnostic catheters; guide wires and torque devices; and angiography and angioplasty accessories. Its cardiology and radiology devices also comprise safety and waste management systems; radial artery compression devices; drainage catheters and accessories; paracentesis, thoracentesis, and pericardiocentesis catheters; therapeutic infusion catheters; embolic microspheres; multipurpose microcatheters; and dialysis and interventional nephrology products. The company also provides gastroenterology and pulmonolog y devices that assist in the palliative treatment of expanding esophageal, tracheobronchial, and biliary strictures caused by malignant tumors. Its gastroenterology and pulmonology devices consist of airway, esophageal, and biliary stents; stent sizing devices; guide wires for non-vascular procedures; bipolar coagulation probes; inflation devices; and cholangiography rapid refill continuous injection kits, as well as specialty devices and accessories, such as discography products and pressure sensors. The company sells its products through direct sales force, distributors, original equipment manufacturer partners, and custom procedure tray manufacturers. Its customers include hospitals and clinic-based cardiologists, radiologists, anesthesiologists, physiatrists, neurologists, nephrologists, vascular surgeons, interventional gastroenterologists and pulmonologists, thoracic surgeons, technicians, and nurses. Merit Medical Systems, Inc. was founded in 1987 and is headquartered in South Jordan, Utah.
Advisors' Opinion:- [By Garrett Cook]
Shares of Merit Medical Systems (NASDAQ: MMSI) were down 15.40 percent to $12.47 after the company reported downbeat quarterly results and issued a weak FY14 forecast.
- [By Garrett Cook]
Shares of Merit Medical Systems (NASDAQ: MMSI) were down 13.64 percent to $12.75 after the company reported downbeat quarterly results and issued a weak FY14 forecast.
No comments:
Post a Comment